Mastering the vast world of PRE-ACT data

Monday, 29 January 2024

High quality data is the key to pragmatic and successful development of Artificial Intelligence (AI) in the clinic to support personalized medicine. Maastro Clinic (Netherlands), its spin-off Medical Data Works, and the French company TheraPanacea are supporting the PRE-ACT consortium in the collection, harmonization, and standardization of multi-modal (images, electronic health records, genomics) and multi-centric data from our institutions. They are working together to build a database including 6000+ patients with breast cancer recruited in REQUITE, CANTO and HYPOG-01 observational and clinical trials. The database includes a comprehensive set of potential clinical, dose-volume, genetic and radiomic predictors which will be used to estimate the risk of radiotherapy-induced toxicities (i.e., arm lymphedema, telangiectasia, skin induration, skin hyperpigmentation, erythema, and edema). We have been through complex yet fascinating challenges while extracting and integrating the dose-volume measures from radiotherapy plans which have been collected in extremely diverse formats. Safe de-identification process of the genomic data and appropriate data augmentation techniques on missing records will remain to be tackled in next steps.